Project Grant R01AA033840
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $301K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $596,476 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the role of acute phase response signaling in alcohol-associated liver disease resolution. The project, awarded as a Project Grant (R01AA032810), funds research examining how hepatocytes direct a resolution program following alcohol cessation, producing signals that alter liver...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $348,662 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate macrophage subset dynamics in the resolution of alcohol-associated liver disease. The project will characterize changes in liver macrophage populations following alcohol cessation, with particular focus on lipid-associated macrophages (LAMs) and their role in fibrosis...
- The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health within the Department of Health and Human Services, awarded $682,736 to Beth Israel Deaconess Medical Center, Inc. on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate myeloid-derived suppressor cells (MDSCs) in alcohol-associated steatohepatitis. The award funds research characterizing MDSC phenotypes and immunoregulatory capacity in alcohol-associated hepatitis...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of Columbia University in the City of New York $2,359,200 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the regulation of hepatocyte functions by hepatic stellate cells in steatotic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated fatty liver disease, and mixed forms. The research characterizes an R-spondin 3-mediated hepatic stellate cell...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $2,072,751 under the Alcohol Research Programs (CFDA 93.273) on September 15, 2025. The recipient is conducting research into innate immune dysregulation in alcohol-associated liver disease, with focus on neutrophil heterogeneity and dysfunction in alcohol-associated hepatitis. The work characterizes transcriptomic profiles and functional roles of neutrophil populations—specifically...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Health Science Center at San Antonio $664,792 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate post-transcriptional mechanisms and cellular senescence in age-related alcoholic liver disease. The research targets dysregulated nutrient sensing as a hallmark of aging that drives hepatic steatosis progression toward cirrhosis and hepatocellular carcinoma. The recipient will...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $456,096 under Project Grant R21AA031889 on September 10, 2025, to explore the role of hepatocyte inflammasome in alcoholic liver disease (AALD). The research investigates how caspase-1, a component of the inflammasome pathway, influences AALD pathophysiology in hepatocytes. The project employs liver-specific genetic deletion models using albumin-cre mice, bulk RNA sequencing, proteomic analysis, and in vitro...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Southwestern Medical Center $478,080 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate ferroptosis propagation in advanced alcoholic liver disease. The project, titled "Combating Advanced Alcoholic Liver Disease by Blocking Intercellular Signaling That Propagates Ferroptosis," addresses a cell death pathway triggered by lipid peroxide accumulation that spreads...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $1.321 million on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate ITPR3 and aberrant mitochondrial calcium signaling in alcoholic hepatitis. The project examines how altered mitochondrial calcium signaling contributes to the development of alcohol-associated hepatitis (AAH), a severe complication of alcohol-associated liver disease with short-term mortality ranging from 20 to 50...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $177,736 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a postdoctoral researcher's career development in understanding the role of neutrophil extracellular traps (NETs) in alcohol-induced acute-on-chronic liver failure. The award funds a two-year mentored research program spanning August 17, 2026, through July 31, 2028, based in Boston, Massachusetts. The...